FDA Approval
FDA Approval
09/15/2026
Anthony Calabro, MA
A 52-week trial evaluated apitegromab-mstn as an adjunct to SMN2-targeted treatment in patients with spinal muscular atrophy who could not move or walk independently, demonstrating improved motor function...
09/15/2026
FDA Approval
FDA Approval
09/15/2026
Anthony Calabro, MA
A 52-week trial evaluated apitegromab-mstn as an adjunct to SMN2-targeted treatment in patients with spinal muscular atrophy who could not move or walk independently, demonstrating improved motor function...
09/15/2026
FDA Approval
FDA Approval
09/15/2026
Anthony Calabro, MA
A 52-week trial evaluated apitegromab-mstn as an adjunct to SMN2-targeted treatment in patients with spinal muscular atrophy who could not move or walk independently, demonstrating improved motor function...
09/15/2026
FDA Approval
FDA Approval
09/15/2026
Anthony Calabro, MA
A 52-week trial evaluated apitegromab-mstn as an adjunct to SMN2-targeted treatment in patients with spinal muscular atrophy who could not move or walk independently, demonstrating improved motor function...
09/15/2026
FDA Approval
FDA Approval
09/15/2026
Anthony Calabro, MA
A 52-week trial evaluated apitegromab-mstn as an adjunct to SMN2-targeted treatment in patients with spinal muscular atrophy who could not move or walk independently, demonstrating improved motor function...
09/15/2026
FDA Alert
FDA Alert
09/08/2026
Anthony Calabro, MA
The approval provides a treatment option for adults and adolescents with warm autoimmune hemolytic anemia who are currently or were previously treated with corticosteroids.
09/08/2026
FDA Alert
FDA Alert
09/08/2026
Anthony Calabro, MA
The approval provides a treatment option for adults and adolescents with warm autoimmune hemolytic anemia who are currently or were previously treated with corticosteroids.
09/08/2026
FDA Alert
FDA Alert
09/08/2026
Anthony Calabro, MA
The approval provides a treatment option for adults and adolescents with warm autoimmune hemolytic anemia who are currently or were previously treated with corticosteroids.
09/08/2026
FDA Alert
FDA Alert
09/08/2026
Anthony Calabro, MA
The approval provides a treatment option for adults and adolescents with warm autoimmune hemolytic anemia who are currently or were previously treated with corticosteroids.
09/08/2026
FDA Alert
FDA Alert
09/08/2026
Anthony Calabro, MA
The approval provides a treatment option for adults and adolescents with warm autoimmune hemolytic anemia who are currently or were previously treated with corticosteroids.
09/08/2026